Edition:
United States

Bioblast Pharma Ltd (ORPN.OQ)

ORPN.OQ on NASDAQ Stock Exchange Capital Market

1.12USD
14 Dec 2018
Change (% chg)

$-0.01 (-0.88%)
Prev Close
$1.13
Open
$1.13
Day's High
$1.13
Day's Low
$1.07
Volume
2,258
Avg. Vol
26,323
52-wk High
$5.99
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Bioblast Pharma reports Q3 loss per share $0.32
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Bioblast Pharma Ltd :Bioblast Pharma reports third quarter 2017 financial results.Q3 loss per share $0.32.  Full Article

Bioblast announces effectiveness of five to one reverse split
Monday, 25 Sep 2017 07:00am EDT 

Sept 25 (Reuters) - Bioblast Pharma Ltd :Bioblast announces effectiveness of five to one reverse split.Bioblast Pharma - ‍trading of ordinary shares on NASDAQ Capital Market will continue, on a split-adjusted basis, with opening of market on Monday​.  Full Article

Bioblast Pharma reports Q2 loss per share $0.10
Friday, 4 Aug 2017 04:15pm EDT 

Aug 4 (Reuters) - Bioblast Pharma Ltd -:Bioblast Pharma reports second quarter 2017 financial results.Q2 loss per share $0.10.Bioblast Pharma Ltd - ‍ Colin Foster and Ralf Rosskamp, MD, have submitted their resignations as members of board, effective August 31, 2017​.  Full Article

Bioblast Pharma to seek strategic alternatives including partnership and merger
Monday, 5 Jun 2017 04:15pm EDT 

June 5 (Reuters) - Bioblast Pharma Ltd ::Bioblast Pharma to seek strategic alternatives including partnership and merger opportunities.Bioblast Pharma Ltd - company receives regulatory clearance to initiate a phase 2b trial of trehalose in opmd patients.Bioblast-At present, ‍not encumbered by license, partnership or royalty arrangements with third parties for development,commercialization of trehalose​.Bioblast Pharma Ltd- it has engaged jsb-partners, a global life sciences advisor, to assist company in executing its "business development objectives".  Full Article

Bioblast Pharma Q1 loss per share $0.16
Friday, 26 May 2017 04:15pm EDT 

May 26 (Reuters) - Bioblast Pharma Ltd :Bioblast pharma reports first quarter 2017 financial results.Q1 loss per share $0.16.Bioblast pharma ltd says pre-commercial expenses were $0.4 million for quarter ended march 31, 2017, compared to $0.8 million for same period in 2016.Bioblast pharma ltd - qtrly loss per share $0.16.Bioblast pharma- cash, cash equivalents and short-term bank deposits as of march 31, 2017, were $7.1 million, compared to $9.9 million as of december 31, 2016.Bioblast pharma ltd - "should we be unable to obtain additional funding required to continue our clinical activity".Bioblast pharma ltd - "we may need to reduce our activities and to explore strategic alternatives until we have sufficient resources".Bioblast pharma ltd - additional funding beyond existing cash resources will be required to entirely cover cost of phase 2b clinical study.  Full Article

Bioblast Pharma posts Q4 loss per share of $0.19
Friday, 24 Feb 2017 08:00am EST 

Bioblast Pharma Ltd : Bioblast pharma reports fourth quarter and year end 2016 financial results . Q4 loss per share $0.19 .Bioblast pharma ltd - cash, cash equivalents and short-term bank deposits as of December 31, 2016 were $9.9 million.  Full Article